Last reviewed · How we verify
Immediate high-intensity statin — Competitive Intelligence Brief
phase 3
HMG-CoA reductase inhibitor (statin)
HMG-CoA reductase
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Immediate high-intensity statin (Immediate high-intensity statin) — Beijing Tiantan Hospital. Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Immediate high-intensity statin TARGET | Immediate high-intensity statin | Beijing Tiantan Hospital | phase 3 | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase | |
| Crestor | rosuvastatin | AstraZeneca | marketed | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase | 2003-01-01 |
| Lipitor | atorvastatin | Pfizer Inc. | marketed | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase | 1996-12-17 |
| Lescol | FLUVASTATIN | Novartis | marketed | HMG-CoA Reductase Inhibitor | HMG-CoA reductase | 1993-01-01 |
| FLUVASTATIN SODIUM | FLUVASTATIN SODIUM | marketed | HMG-CoA reductase | 1993-01-01 | ||
| Simvastatin-Methylcellulose | Simvastatin-Methylcellulose | University of Nebraska | marketed | HMG-CoA reductase inhibitor (statin) | HMG-CoA reductase | |
| sirolimus, mycophenolat mofetil, fluvastatin | sirolimus, mycophenolat mofetil, fluvastatin | University Hospital Schleswig-Holstein | marketed | Immunosuppressive combination therapy with statin | mTOR, IMPDH, HMG-CoA reductase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (HMG-CoA reductase inhibitor (statin) class)
- Organon and Co · 7 drugs in this class
- Kuhnil Pharmaceutical Co., Ltd. · 3 drugs in this class
- Wenzhou Medical University · 2 drugs in this class
- Amgen · 2 drugs in this class
- Beijing Tiantan Hospital · 2 drugs in this class
- Seoul National University Hospital · 2 drugs in this class
- JW Pharmaceutical · 2 drugs in this class
- AstraZeneca · 2 drugs in this class
- Korea University Anam Hospital · 2 drugs in this class
- Gachon University Gil Medical Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Immediate high-intensity statin CI watch — RSS
- Immediate high-intensity statin CI watch — Atom
- Immediate high-intensity statin CI watch — JSON
- Immediate high-intensity statin alone — RSS
- Whole HMG-CoA reductase inhibitor (statin) class — RSS
Cite this brief
Drug Landscape (2026). Immediate high-intensity statin — Competitive Intelligence Brief. https://druglandscape.com/ci/immediate-high-intensity-statin. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing